| 1,285 | 19 | 47 |
| 下载次数 | 被引频次 | 阅读次数 |
抑郁症目前正成为全球健康的巨大威胁，主要以情绪低落、思维活动迟缓、意志显著抑制等为核心症状，同时可能伴有一些植物神经功能紊乱的症状，如疲劳、体质量减轻、食欲不振和失眠等。传统抗抑郁药物对抑郁症的治疗作用单一局限，且不良反应明显。中医历代医家总结治疗郁证的关键为从肝论治，气为关键，健脾为要，顺和之势。而逍遥散具有疏肝解郁、养血健脾的功效，并且从神经递质、氧化应激、神经生长因子、炎症细胞因子、神经细胞凋亡相关蛋白和微生物-肠-脑轴等多个方面进行实验研究，分析证明了逍遥散对抑郁症的治疗有多位靶点、方位全面、安全性高的特点。但目前关于逍遥散在临床观察方面的高质量文献不足，缺乏多中心多样本的研究；同时实验室研究中缺乏具有中医特色的疾病证型；最后还可以从网络药理学入手，观察各具体成分的作用机制及相互之间的联系。
Abstract：Depression is now becoming a huge threat to global health,mainly with low mood,slow thinking activity,significant suppression of will as the core symptoms,and may be accompanied by some symptoms of autonomic nerve dysfunction,such as fatigue,weight loss,loss of appetite and insomnia. The therapeutic effect of traditional antidepressants on depression is limited,and the side effects are obvious.Physicians of all dynasties of traditional Chinese medicine have concluded that the key to the treatment of depression is the treatment of the liver,Qi as the key,invigorating the spleen,and the harmony. Xiaoyao Powder（逍 遥 散）has the functions of soothing the liver and relieving depression,nourishing blood and strengthening the spleen,and experiments have been carried out on neurotransmitters,oxidative stress,nerve growth factors,inflammatory cytokines,nerve cell apoptosis-related proteins,and brain-gut axis.Research and analysis have proved that Xiaoyao Powder has the characteristics of multiple targets,comprehensive orientation and high safety in the treatment of depression. However,there is insufficient high-quality literature on clinical observation of Xiaoyao Powder,and a lack of multi-center and multisample studies. At the same time,there is a lack of disease syndromes with TCM characteristics in laboratory research. Finally,we can start from network pharmacology to observe the mechanisms of action and interrelationships of specific components.
[1] K?NIG H,K?NIG H H,KONNOPKA A. The excess costs of depression:a systematic review and meta-analysis[J]. Epidemiol Psychiatr Sci,2019,29:e30.
[2] World Health Organization. Depression and other common mental disorders:global health estimates[M]. Geneva:World Health Organization,2017.
[3]张莉莉，王蕾，周毅德，等.仝小林“慢病十态”之调态方略简析[J].中医杂志，2021,62(11):934-942.
[4]李亚慧，赵红霞，高蕊.中医郁证病名解析[J].中国中医基础医学杂志2020,26(4):430-432.
[5]张社峰.国医大师张磊运用逍遥散经验拾萃[J].新中医，2021,5(38):34-38.
[6]潘凯婷，王亚丽.王亚丽教授辨治郁证经验总结[J].亚太传统医药，2018,14(1):131-132.
[7]陈佳飞，邵琼琰，陈丽琼，等.张永华治疗郁证经验[J].浙江中西医结合杂志，2018,28(12):990-991.
[8]汪艳.吴炳忠.丹栀逍遥散治疗郁证经验[J].实用中医内科杂志，2012,26(12):11-12.
[9]贾广成，郑兴宇，周玉枝，等.逍遥散对CUMS模型大鼠行为学及血浆内单胺类神经递质的影响[J].中国实验方剂学杂志，2011,17(6):136-140.
[10]何敏，刘金伟，龚锡平，等.逍遥散对嗅球摘除抑郁模型大鼠的抗抑郁作用机制研究[J].中药药理与临床，2014,30(5):14-17.
[11]侯璐璐，周仁来.奖赏进程失调在情绪障碍产生中的作用[J].中国临床心理学杂志，2019,27(5):878-882.
[12] SEDAGHAT K,YOUSEFIAN Z,VAFAEI A A,et al.Mesolimbic dopamine system and its modulation by vitamin D in a chronic mild stress model of depression in the rat[J].Behav Brain Res,2019,356:156-169.
[13]梁媛，张欢润，岳广欣，等.逍遥散对慢性轻度不可预见应激抑郁模型大鼠伏核脑区多巴胺及其受体、转运体的调节作用[J].中华中医药杂志，2021,36(10):6132-6136.
[14]童萍.基于GAT-2探讨抑郁症肝郁脾虚证及逍遥散干预机制[D].扬州：扬州大学，2021.
[15]罗杰，刘小波，吕红君，等.逍遥散对抑郁大鼠的行为学及抗氧化作用的影响[J].中成药，2019,41(12):2869-2875.
[16]付劭静，周延华，卑红喆，等.逍遥散对卒中后抑郁大鼠的治疗机制研究[J].广州中医药大学学报，2022,39(5):1135-1142.
[17]罗杰，方洋，曾九僧，等.基于PI3K-AKT-Nrf2/BDNF通路研究逍遥散抗抑郁作用的机制[J].中药药理与临床，2019,35(6):2-6.
[18]许亚辉，吴佳佳，严志祎，等.逍遥散对慢性应激抑郁大鼠海马一氧化氮合酶表达的影响[J].中华中医药杂志，2019,34(12):5679-5683.
[19]韩海洋，彭淑芹，徐向东.逍遥散对抑郁模型大鼠海马中枢神经递质含量及BDNF和TrkB表达的影响[J].长春中医药大学学报，2015;31(5):893-896.
[20]刘燕，吴耀松，杨铁柱，等.基于胶质细胞增值调控因子bFGF/TGF-β1探讨逍遥散治疗抑郁症的机制[J].世界科学技术-中医药现代化，2020,22(9):3288-3293.
[21]陶希，刘佳，邓景贵，等.低频重复经颅磁刺激对卒中后抑郁的远期疗效及血5-羟色胺表达的影响[J].中华物理医学与康复杂志，2014,36(6):416-420.
[22]万小敏，周蓉，黄昕彤，等.逍遥散对慢性不可预知温和应激肝郁脾虚型抑郁症大鼠海马区IL-6、TNF-α影响[J].辽宁中医药大学学报，2020,22(2):47-51.
[23]刘玥芸，高静静，赵歆，等.逍遥散对慢性轻度不可预见应激抑郁大鼠性行为及炎性细胞因子的影响[J].国际中医中药杂志，2019,41(11):1208-1212.
[24]石博宇，罗杰，饶志粒等.逍遥散对LPS诱导的抑郁样大鼠的干预作用及机制研究[J].中药药理与临床，2018,34(6):3-7.
[25] DE BOSSCHER K,VANDEN BERGHE W,HAEGEMAN G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids:negative interference of activated glucocorticoidreceptor with transcription factors[J]. J Neuroimmunol,2000,109(1):16-22.
[26]佘楷杰，高静静，巩子汉，等.母婴分离/束缚应激模型小鼠海马小胶质细胞变化及温阳解郁方的调节作用[J].中国实验方剂学杂志，2021,27(18):49-57.
[27]单楠，谭子虎，杨冰，等.逍遥散促进小胶质细胞极化改善血管性痴呆伴抑郁小鼠髓鞘再生及抑郁表型[J].中国实验方剂学杂志，2021,27(19):19-27.
[28]侯雅静.基于miR-29b抑制海马神经元凋亡探究逍遥散及芍药苷抗抑郁作用机制[D].北京：北京中医药大学，2021.
[29]纪雅菲，芮翊馨，方洋，等.逍遥散正丁醇部位基于IGF-1Rβ/PI3K/Akt信号通路的抗抑郁作用[J].中国实验方剂学杂志，2021,27(14):1-11.
[30]胡靖文，谢志强，方洋，等.逍遥散乙酸乙酯部位对LPS致抑郁样模型小鼠影响的实验研究[J].中药药理与临床，2022,38(2):37-43.
[31] HATTORI N,YAMASHIRO Y. The Gut-Brain Axis[J].Ann Nutr Metab,2021,77(2):1-3.
[32]徐春悦，李宝玲.基于中西医维度对脑肠轴的探讨[J].中医研究，2021,34(4):6-9.
[33] AIZAWA E,TSUJI H,ASAHARA T,et al. Possible association of Bifidobacterium and Lactobacillus in the gut microbiota of patients with major depressive disorder[J]. Affect Disord,2016,202:254-257.
[34] LIU X,LV M,WANG Y,et al.Anti-depressive effects of Xiaoyaosan,Shugan and Jianpi herbal treatments:Role on the gut microbiome of CUMS rats.[J]. Phytomedicine,2021,87:153581.
[35] ZHU H Z,LIANG Y D,MA Q Y,et al.Xiaoyaosan improves depressive like behavior in rats with chronic immobilization stress through modulation of the gut microbiota[J]. Biomed Pharmacother,2019,112:108621.
[36]张兆洲，邵诗芸，贾茹，等.逍遥散对慢性束缚应激大肠癌裸鼠肠道菌群代谢产物的影响[J].中华中医药杂志，2022,37(3):1740-1743.
[37]梁媛，岳利峰，张欢润，等.慢性轻度不可预见应激模型大鼠下丘脑食欲调节因子的变化及逍遥散的作用研究[J].北京中医药大学学报，2021,44(5):428-435.
[38]梁媛，高静静，刘玥芸，等.逍遥散对慢性轻度不可预见应激抑郁大鼠行为学及食欲调节因子的影响[J].中国中医基础医学杂志，2019,25(11):1541-1543,1561.
[39]王一旭，李媛媛，张碧涛，等.逍遥散对慢性不可预知温和应激大鼠下丘脑弓状核JAK/STAT通路变化的影响[J].中国实验方剂学杂志，2020,26(21):21-27.
[40] DING F,WU J,LIU C,et al.Effect of Xiaoyaosan on Colon Morphology and Intestinal Permeability in Rats With Chronic Unpredictable Mild Stress[J]. Front Pharmacol,2020,11:1069.
[41]丁凤敏，吴佳佳，邹小娟，等.逍遥散对抑郁模型大鼠下丘脑、结肠中P物质和血管活性肠肽的影响[J].中华中医药杂志，2020,35(7):3350-3352.
[42] BUROKAS A,ARBOLEYA S,MOLONEY RD,et al.Targeting the Microbiota-Gut-Brain Axis:Prebiotics Have Anxiolytic and Antidepressant-like Effects and Reverse the Impact of Chronic Stress in Mice[J]. Biol Psychiatry,2017,82(7):472-487.
[43] WANG Z Y,WANG X,ZHANG D Y,et al. Traditional Chinese medicine network pharmacology:development in new era under guidance of network pharmacology evaluation method guidance[J]. Zhongguo Zhong Yao Za Zhi,2022,47(1):7-17.
基本信息:
DOI：10.13194/j.issn.1673-842x.2023.02.032
中图分类号:R277.7
引用信息:
[1]常人瑞,王亚丽,张英美,等.逍遥散治疗抑郁症相关作用机制研究探讨[J].辽宁中医药大学学报,2023,25(02):157-161.DOI:10.13194/j.issn.1673-842x.2023.02.032.
基金信息:
国家自然科学基金项目（30973829）
2022-07-25
2022-07-25
2022-07-25